Amedeo Smart

Free Medical Literature Service



Alzheimer's Disease

  Free Subscription

Articles published in
JAMA Intern Med
    June 2022
  1. WOLOSHIN S, Kesselheim AS
    What to Know About the Alzheimer Drug Aducanumab (Aduhelm).
    JAMA Intern Med. 2022 Jun 6. pii: 2792897. doi: 10.1001/jamainternmed.2022.1039.
    >> Share

    March 2022
  2. PALAN LOPEZ R, Hendricksen M, McCarthy EP, Mazor KM, et al
    Association of Nursing Home Organizational Culture and Staff Perspectives With Variability in Advanced Dementia Care: The ADVANCE Study.
    JAMA Intern Med. 2022;182:313-323.
    >> Share

    February 2022
  3. LEE CS, Gibbons LE, Lee AY, Yanagihara RT, et al
    Association Between Cataract Extraction and Development of Dementia.
    JAMA Intern Med. 2022;182:134-141.
    >> Share

    December 2021
  4. LARGENT EA, Peterson A, Lynch HF
    FDA Drug Approval and the Ethics of Desperation.
    JAMA Intern Med. 2021;181:1555-1556.
    >> Share

    October 2021
  5. CROSSON FJ, Covinsky K, Redberg RF
    Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity?
    JAMA Intern Med. 2021;181:1278-1280.
    >> Share

    July 2021
    The Accelerated Approval of Aducanumab for Treatment of Patients With Alzheimer Disease.
    JAMA Intern Med. 2021 Jul 13. pii: 2782122. doi: 10.1001/jamainternmed.2021.4622
    >> Share

  7. DUNN B, Stein P, Cavazzoni P
    Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective.
    JAMA Intern Med. 2021 Jul 13. pii: 2782119. doi: 10.1001/jamainternmed.2021.4607
    >> Share

  8. MITCHELL SL, D'Agata EMC, Hanson LC, Loizeau AJ, et al
    The Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer Disease and Other Dementias (TRAIN-AD): A Cluster Randomized Clinical Trial.
    JAMA Intern Med. 2021 Jul 12. pii: 2782003. doi: 10.1001/jamainternmed.2021.3098
    >> Share

    November 2020
  9. NICHOLAS LH, Langa KM, Bynum JPW, Hsu JW, et al
    Financial Presentation of Alzheimer Disease and Related Dementias.
    JAMA Intern Med. 2020 Nov 30. pii: 2773241. doi: 10.1001/jamainternmed.2020.6432
    >> Share

    December 2019
  10. BURKE JF, Langa KM
    Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease-Reply.
    JAMA Intern Med. 2019;179:1737.
    >> Share

  11. RABINOVICI GD, Carrillo MC
    Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease.
    JAMA Intern Med. 2019;179:1736-1737.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016